Ad hoc announcement pursuant to Art. 53 LR

Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued

Zur Rose Group AG / Key word(s): Annual Results
Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued

24-March-2022 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Frauenfeld, 24 March 2022
Press release
Ad hoc announcement pursuant to Art. 53 LR

Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued

- Zur Rose ready for the launch of e-prescriptions in Germany

- Use of the delayed launch of e-prescriptions: short term leveraging of synergies and focus on profitability

- Set up of the healthcare ecosystem progressing rapidly

- New logistics centre in Heerlen to go into operation

- Matthias Peuckert succeeds Walter Hess as Head Germany

The Zur Rose Group continued to rigorously pursue the growth strategy in 2021 - in particular seizing the opportunities arising from electronic prescriptions in Germany and internationalisation. The successful launch of the DocMorris healthcare app in 2021 created a central, easily accessible portfolio of healthcare services and laid the technical foundations for recording and forwarding e-prescription information. In France the Group extended the product range with a strategic partner by including OTC medications, giving customers easy and secure access to a broad range of health-related products and pharmaceutical advice. In this dynamic environment the Zur Rose Group raised CHF 188.5 million in a capital increase at the end of 2021, which was intended to be mainly used for e-prescriptions when they were launched nationally in Germany; however, this was unexpectedly deferred at the end of the year.

Result in line with expectations
External revenue1 rose 15.5 per cent to CHF 2,034.0 million, meaning the Zur Rose Group met forecasts in the second year of the pandemic. Growth continued in all market segments: Switzerland, Germany and Europe. The number of active customers rose by more than 18 per cent year on year in 2021 to 12.4 million.2 To support the growth strategy, the Zur Rose Group is investing heavily in electronic prescriptions and high-margin future areas: the healthcare ecosystem, telemedicine and PaaS (Platform as a Service). As the European umbrella brand for the ecosystem and with a view to the mandatory launch of e-prescriptions originally set for the start of 2022, in February 2021 DocMorris started a large-scale marketing campaign in Germany on the theme "Das neue Gesund". In total, expenses for these activities were up roughly CHF 60 million year on year. The OTC market stagnated because of the pandemic, so growth costs were higher, which had an impact on the margin and the marketing ratio. One-off expenses also affected the result, mainly in connection with acquisitions and restructurings. EBITDA adjusted for one-off effects came to minus CHF 128.9 million, putting it in line with expectations. The operating result (EBITDA) was minus CHF 142.6 million.

Starting basis laid for the launch of electronic prescriptions in Germany
The Zur Rose Group is technically and logistically ready for the national launch of electronic prescriptions in Germany, which is still expected to take place this year despite the delay. DocMorris used 2021 to focus its healthcare app even more closely on customer needs. This has now been downloaded more than 1.3 million times, making it one of the fastest growing healthcare apps. It provides direct access to physical doctors and the telemedical offering, seamless and personalised customer journeys, adherence solutions, same day delivery options and marketplace offerings. A handy scan function for having e-prescriptions dispensed makes it possible to transmit digital prescription information to the desired pharmacy quickly and securely. As part of the test phase, more than 200 e-prescriptions have already been successfully dispensed by DocMorris and partner pharmacies in the Germany segment. The logistics extension in Heerlen will go into operation in the second quarter of 2022 to handle the volumes expected. The state-of-the-art technology will raise the level of automation to 70 per cent and more than double the site's capacity.

Recognition of the DocMorris umbrella brand increases
The Zur Rose Group launched a national multimedia campaign for the DocMorris brand in 2021 on the theme of "Das neue Gesund" to convey the new brand values following the extensive rebranding. The new campaign showcased the brand as an approachable and reliable partner and makes the digital services on the healthcare platform come alive. DocMorris won numerous awards for the new branding. By the end of the year, supported brand recognition had risen to over 70 per cent.

Strategic partnerships for innovative health journeys
The Zur Rose Group continued to expand the European healthcare ecosystem under the DocMorris umbrella brand. This is being gradually anchored in all business units and segments. Telemedicine, marketplace and pharmacy services are already available in the DocMorris app. The Zur Rose Group also entered into two ecosystem partnerships in 2021. In collaboration with Novo Nordisk, it launched the first customer-centric health journey for people living with obesity. The offering helps those affected find their way to the best possible treatment. Initially, the focus is on Germany. Another partnership, with Roche Diabetes, brings together both companies' healthcare products with solutions and high-quality services from third parties to make life easier for people with diabetes.

Continuing the transformation into a tech company
The Zur Rose Group further drove ahead the transformation into a technology company in 2021. Interdisciplinary teams in the three tech hubs in Barcelona, Winterthur and Berlin are working at a European level to make customer journeys more intuitive, user-focused and seamless. The Group is also focused on further developing and building up platform technologies and offers platform as a service and marketplace as a service models to partners from the beauty and personal care sector in particular. The benefit for these companies lies not only in gaining visibility, traffic and reach, but also in establishing a new sales channel. A multi-channel strategy allows them to both strengthen their own brand and provide optimal and seamless customer service. The Zur Rose Group also contributed its technology expertise to the healthcare app launched by Swiss healthcare platform Well in late summer 2021.

apo-rot merged with DocMorris
apo-rot B.V. merged with DocMorris N.V. as at 30 June 2021. All employees were taken over and integrated into the existing structures at the Heerlen site. The Zur Rose Group has therefore completed the next step of the integration towards achieving efficiency improvements.

Changes to the Board of Directors
As announced, CEO Walter Oberhänsli will be put forward for election as Chairman at the Annual General Meeting of Shareholders on 28 April 2022. Chairman Prof. Stefan Feuerstein will take on the role of Vice Chairman. Dr. Thomas Schneider, Vice Chairman, and Prof. Dr. Volker Amelung will not be standing for re-election. On 10 January 2022, the Zur Rose Group announced the nomination of Rongrong Hu as a new director. In the event that all proposed persons are elected, the Board of Directors will shrink from its current seven members to six and one-third of these will be female. This means the Board's target of achieving at least 30 per cent female members by 2023, announced in the 2020 Annual Report, will be reached a year ahead of schedule.

Matthias Peuckert to be Head Germany
Following the Annual General Meeting of Shareholders Matthias Peuckert, who since 2018 has been CEO of, a Munich-based online retailer of baby and children's articles, will become Head Germany and CEO of DocMorris. He will be stepping into the shoes of Walter Hess, who will succeed Walter Oberhänsli as CEO of the Zur Rose Group after the General Meeting. Matthias Peuckert will share considerable responsibility for driving ahead growth in the core German market and provide major impetus for further expanding the European healthcare ecosystem. The 48-year old German citizen is a proven expert in e-commerce with broad experience at listed companies, including internationally. He can look back on 14 years at Amazon, where he was most recently Group Director for Core Consumables Germany and Amazon Pantry Europe with responsibility for revenue in the low single-digit billions and several key strategic projects.

First sustainability report lays the basis for further improvements
Today the Zur Rose Group published its first sustainability report. The main pillars of the sustainability strategy have been defined as healthy people, healthy planet, healthy company and healthy relationships. On this basis, the Group has set seven sustainable development goals (SDGs), which match those of the United Nations. In 2022 Zur Rose will set specific targets for the areas defined as the basis for further improvements.

Focus for 2022: e-prescriptions and leveraging synergies
The first focus for 2022 is electronic prescriptions in Germany. With around 11 million active customers2, DocMorris is the best known pharmacy brand and one of the most successful healthcare apps in the German market; this gives the Zur Rose Group an excellent starting position to convince customers of its service offering and win them over to e-prescriptions. The Group is also keen to leverage efficiencies through synergies. The emphasis is on creating cross-border shared service functions, pooling expertise and using a common platform for technology, products, logistics, services and brands. This will lay solid foundations for further expansion and sustainable profitability at the Zur Rose Group.

Management is confident that the business with prescription medications on the basis of electronic prescriptions (eRx) in Germany will get under way this year. However, since the timing is not confirmed, the Zur Rose Group is excluding the influence of eRx for 2022. The objective for the core DocMorris brand is double-digit growth in non-prescription products. At the Group level, the focus in the short term is on operational leverage and profitability, so external revenue is likely to remain flat year on year. For 2022, management is aiming for adjusted EBITDA between minus CHF 75 million and minus CHF 95 million driven by continued investment in technology and maintaining eRx readiness. As a result of the delay in eRx, break even at the EBITDA level is expected in 2024. The Group confirms the medium-term EBITDA margin target of around 8 per cent.

Key financials, in million CHF 2021 2020
External revenue1 2,034.0 1,761.7
Year-on-year-change of external revenue in % in local currency 14.8% 15.1%
Year-on-year change of external revenue in % 15.5% 12.3%
Net revenue 1,726.5 1,476.9
Year-on-year change of net revenue in % 16.9% 9.0%
Gross margin in % of net revenue 15.1% 16.3%

Earnings before interest, taxes, depreciation and amortisation (EBITDA) adjusted
-128.9 -31.2
in % of net revenue -7.5% -2.1%
Earnings before interest, taxes, depreciation and amortisation (EBITDA) -142.6 -78.4
in % of net revenue -8.3% -5.3%
Earnings before interest and taxes (EBIT) -193.8 -117.6
in % of net revenue -11.2% -8.0%
Net operating income -225.7 -135.6
in % of net revenue -13.1% -9.2%
Equity 484.9 531.7
in % of total assets 38.2% 41.6%
Investments 63.5 59.8
Number of employees (in full-time equivalents) 2'131 1'960

1) External revenue consists of the consolidated revenue of the Zur Rose Group plus online revenues of pharmacies supplied by the Zur Rose Group, less the consolidated revenue from supplying them. The definition was slightly revised in 2021 and the figures for the previous year restated accordingly.

2) Customers supplied by the Zur Rose Group in 2021, either directly or through its partners.

The full online 2021 Annual Report can be found at

At 11 a.m. CET today there will be a telephone conference in English for analysts and the media.
CH: 41 (0)44 580 7279 | DE: +49 (0)69 22222 5197 | UK: +44 (0)330 165 4012 | USA: +1 323-701-0160
Conference ID: 5263923
The associated presentation is available at:
Alternatively, the presentation can be followed via live audio webcast using the following link:

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email:, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email:, phone: +41 52 724 08 14

20 April 2022 First Quarter Trading Update
28 April 2022 Annual General Meeting
18 August 2022 Half-Year Results
20 October 2022 Q3 Trading Update

Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,400 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 12 million active customers in core European markets, Zur Rose generated external revenue of CHF 2,034 million in 2021.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care, as well as digital services relating to marketplaces, ecosystems, technology and telemedicine. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up and extending its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Its ambition is to provide customer-centred health journeys so people are offered optimum supply and a range of medication and treatment options. By doing so, Zur Rose is pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit

Additional features:

File: en

End of ad hoc announcement
Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Phone: +41 52 724 08 14
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1310191

End of Announcement EQS News Service

1310191  24-March-2022 CET/CEST